<DOC>
	<DOCNO>NCT01408797</DOCNO>
	<brief_summary>The objective trial determine clonal deletion kidney transplantation effectively reduce need post transplant immunosuppression . The investigator adapt DAWN ( Drugs ( immunosuppressant ) Added When Needed ) treatment protocol assess effect clonal deletion closely monitor acute rejection , renal function , graft survival . 15 patient eligible study describe enrol .</brief_summary>
	<brief_title>Clonal Deletion Living-Relative Donor Kidney Transplantation</brief_title>
	<detailed_description>The objective trial determine clonal deletion effectively reduce need post transplant immunosuppressive medicine . Emphasis place adverse event associate clonal deletion . The investigator assess whether DAWN ( Drugs ( immunosuppressant ) Added When Needed ) feasible living-relative donor kidney transplantation effectiveness clonal deletion treatment rate rejection , patient survival , graft function day 0 12 month transplantation . Numbers patient single drug dual therapy immunosuppression count . Additionally , investigator would assess time immune event ( rejection antibody ) , severity acute rejection antibody mediate rejection Banff criterion , incidence delay graft function ( defined need post-transplant dialysis ) , incidence adverse event include infection , grade 3 non-hematologic toxicity , grade 4 hematologic toxicity .</detailed_description>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Uremia patient race great equal 18 year age less 60 year old 2 . Recipients kidney certifiable relative donor 1860 year age 3 . Patient willing capable give write informed consent study participation able participate study 12 month 1 . Women pregnant , intend become pregnant next 1 year , breastfeeding , positive pregnancy test enrollment prior study medication administration 2 . Patient prior solid organ transplant cell transplant ( e.g . bone marrow islet cell ) . 3 . Patient deem likely second solid organ transplant cell transplant ( e.g . bone marrow islet cell ) next 3 year 4 . Patient receive concurrent SOT ( heart , liver , pancreas ) cell transplant ( islet , bone marrow , stem cell ) 5 . ABO incompatible donor recipient pair CDC crossmatch positive transplant 6 . Sensitized patient ( recent antiHLA Class I II Panel Reactive Antibodies ( PRA ) &gt; 0 % CDCassay ) patient identify high immunological risk transplant physician 7 . Donor cardiac death ( nonheart beat donor ) 8 . Recipient CMV seronegative receive organ seropositive donor ( CMV seromismatch ) 9 . Donor OR Recipient know hepatitis C antibodypositive polymerase chain reaction ( PCR ) positive hepatitis C 10 . Donors OR Recipient know hepatitis B surface antigenpositive PCR positive hepatitis B AND recipient HBV negative 11 . Patient and/or donor know human immunodeficiency virus ( HIV ) infection 12 . Patient risk tuberculosis ( TB ) Current clinical , radiographic , laboratory evidence active latent TB determine local standard care History active TB : Within last 2 year , even treat Greater 2 year ago , unless documentation adequate treatment accord locally accept clinical practice Patient risk reactivation TB preclude administration conventional immunosuppression ( determine investigator base upon appropriate evaluation ) 13 . Patient significant infection contraindication would preclude transplant 14 . Patient history hypercoaguable state 15 . Patient history substance abuse ( drug alcohol ) within past 6 month , psychotic disorder compatible adequate study followup . 16 . Patient active peptic ulcer disease ( PUD ) , chronic diarrhea , gastrointestinal malabsorption 17 . Patient history cancer within last 5 year ( exception : nonmelanoma skin cell cancer cure local resection permit ) 18 . Patient chest radiograph ( 2 month prior randomization ) consistent acute lung parenchymal process malignancy 19 . Patient hypersensitivity study drug 20 . Patient use investigational drug within 30 day prior Day 1 visit 21. . Patients autoimmune disease patient treat immunosuppressive therapy ( eg methotrexate , abatacept , etc ) indication autoimmune disease patient comorbidity degree treatment agent likely trial 22 . Prisoner patient compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g . infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>clonal deletion</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>